Rivaroxaban, an anticoagulant used to prevent and treat thrombosis, was the medicine that rose the most in value
Medicines rose in price by up to 359% in 2024. The comparison is between January and December of the same year. The data are from a tool that compares prices of medicines and other pharmaceutical items.
Rivaroxaban, an anticoagulant used to prevent and treat thrombosis, was the medicine whose value rose the most in the period (359%). It was followed by prednisolone, a corticosteroid that treats inflammation and autoimmune diseases, relieving swelling and allergies (340%). Closing the top 3 comes tadalafil, used to treat erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension (328%).
According to the data, the increases can be explained, in general, by a combination of economic (inflation and exchange rate), logistical (supply chain and increase in the cost of inputs) and commercial (high demand and low competition in specific medicines) factors. .
“Many of these medications are also used for critical or chronic conditions, which makes them more susceptible to wide price fluctuations.”said to .
CMED (Chamber of Medicines Market Regulation) authorized in 2024 an adjustment of up to 4.5% in the values charged for medicines in Brazil. Values above 300%, however, exceed the percentage stipulated last year.
To arrive at the index, CMED observed factors such as inflation in the last 12 months, productivity of the pharmaceutical industries, costs not captured by inflation, such as exchange rate and electricity tariffs and market competition, as determined by the calculation defined since 2005.
